nostically significant. The results were compared with histology and pathological stage of the primary tumour in patients presenting with lung metastases but no clinical evidence of lymph-node disease. Embryonal carcinoma was more commonly associated with a locally invasive primary tumour and with extralymphatic spread than was teratocarcinoma.
THE RESULTS OF TREATMENT at this centre for patients with clinical Stage I non-seminomatous germ-cell tumours of the testis (NSGCTT) managed by elective lymph-node irradiation following orchidectomy have been reported previously (Peckham, 1979) . With this approach -20% of patients relapse, disease recurring predominantly in the lungs and supradiaphragmatic lymph nodes (Peckham et al., 1977) . The early detection of relapse and prompt institution of chemotherapy results in excellent survival figures . However, in order to avoid inessential therapy it would be advantageous if the group of patients with a high probability of relapse after radiotherapy could be identified prospectively.
It is known, from comparisons of lymphography with lymph-node histology, that 250 of clinical Stage I patients have sub-clinical retroperitoneal node metastases and that the probability of eradicating them with radiotherapy is high (Peckham et al., 1977) . Growth-rate measurements on lung metastases in patients relapsing after irradiation suggest that in most patients pulmonary spread has occurred by the time of initial diagnosis (Peckham et al., 1977) . Computerized axial X-ray tomographic (CAT) scanning of the lungs will identify a proportion, but not all, of this group initially (Husband et al., 1981) .
The prognostic significance of serum o-foetoprotein (AFP) and f-human chorionic gonadotrophin (B-hCG) (Pugh & Cameron, 1976) Pathological staging.-The local extent of the primary tumour was classified using the criteria of the BTTP (Pugh & Cameron, 1976) (Heyderman & Neville, 1976; Heyderman, 1977 Peto et al. (1976 Peto et al. ( , 1977 .
RESULTS (A) Stage I patients
Patient age and side of the tumour.
The 59 males included in the study ranged in age from 17-60 years (mean 29-6 years) at presentation. The tumour was on the left in 29 patients, right in 29 patients and bilateral in 1 man. Side of presentation and age did not influence outcome of treatment.
Histology of the primary tumour.-As shown in Table I it is possible that the true percentage of AFP-positive patients is higher. Serum AFP levels ranged from 31 to 3000 p,g/l,
but there was no correlation between serum level and prognosis. Of the 18 patients with raised AFP levels, 5 relapsed (Fig. 1 ).
Only 5 (8.5%) men had raised hCG levels (Table II) , but since the normal half-life of serum hCG is 24-36 h it is highly probable that the true number with raised hCG serum levels at the time of orchidectomy was higher. In 3/5 hCG+ cases, assay was performed on the day of orchidectomy.
Tissue HOG.-Tissue sections were stained immunocytochemically for hCG in 48 patients, and were positive in 27 (56.2%). As shown in Table III, in 21 tissue-positive patients, serum hCG levels were normal in 18 when they were referred to the Royal Marsden Hospital. This may well reflect rapid clearance from the blood when the primary tumour is removed. One tissue-negative patient showed high serum levels of hCG. Presence of hCG in tissue sections had no prognostic significance. Six of 27 (22.2%) tissuepositive patients relapsed, compared with 7/21 (33%) tissue-negative patients.
Changes in serum marker levels between orchidectomy and radiotherapy.-As shown in Table IV , patients were divided into two groups, A and B. In Group A there was evidence that serum marker levels were either persistently negative before irradiation or, if high, they fell with a half-life consistent with the removal of all the tumour (AFP: 6-7 days, hCG: 24-36 h).
Group B included patients with persistently high serum marker levels, and those with a slow rate of fall after orchidectomy. If only one value was available several weeks after orchidectomy and before GIroup B patients. This difference is significant (P < 001). The disease-free survival curves are shown in Fig. 2 . Relapse pattern and patient survival. Of the 14 patients who relapsed, the pattern was as follows: left cervical nodes (3), lung ± mediastinal nodes (7), brain/lung (1), groin nodes (1), abdominal nodes + extralymphatic metastases (2). Seven patients were successfully treated for relapse and 52/59 (88%0) of the patients are alive and disease-free. There were 5 (8%) tumour deaths, I died of a cerebrovascular accident and 1 of complications relating to chemotherapy.
(B) Stage I Vo Li L2 and L3 patients This group was examined with respect to histology and pathological stage of the primary tumour, and compared with the findings described above in Stage 1 disease. Fig. 3 shows that, whereas in Stage I there is a preponderance of MTI primary tumours, the commonest sub-type in IVO L1l3 is MTU.
As shown in Fig. 4 Age at presentation and side of primary tumour had no influence on relapse rate. In previous analyses on a larger number of patients the relapse rate for patients with MTU primaries was significantly greater than that for MTI (Peckham et al., 1977) . In the present smaller series no significant difference was observed.
The observations made in Stage I patients and patients presenting with lung metastases and no evidence of lymph-node disease indicate that MTU is associated with a higher probability of cord involvement than is MTI.
Extent of the primary tumour was a significant prognostic factor, there being an increased incidence of relapses in patients with tumour involving spermatic cord, epididymis or scrotal sac (P< 0 01). This agrees well with the increased incidence of P2 and P3 stages in a group of patients presumed to have haematogenous spread without clinical evidence of nodal deposits at presentation. An important prognostic indicator in this series was the rate of decline of serum AFP and hCG levels after orchidectomy. Thus the relapse rate in patients with negative or rapidly falling markers was significantly less than in patients with a protracted decline (16% vs 60% respectively; P < 0 01).
Because of the delay in referral following orchidectomy, the estimated incidences of 30.500 for patients with high AFP levels is probably artificially low, since the half-life of serum AFP is 7 days. Since the average delay in referral was 21 days, patients with pre-orchidectomy levels of 25-200 tmg/l may have had undetectable levels on referral. This applies even more to hCG, the half-life of which is [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] h. This may well explain why only 3/27 patients with immunocytochemically demonstrable hCG in primary tumour tissue had high serum hCG levels on referral. The frequency of hCG + tissue (56.2%) may reflect the proportion of patients with elevated serum hCG levels more accurately. The presence of immunocytochemically demonstrable hCG did not influence prognosis. Similarly, no significant difference was observed in rates of relapse between patients with initially normal and high serum marker levels (Fig. 1) . However, because of the delay in most patients between orchidectomy and first assay, and the possibility that a proportion of men with normal serum marker levels at referral may have had high levels at orchidectomy, the true significance of serum-marker status cannot be fully assessed.
The present study has the disadvantage of being a retrospective analysis of a relatively small number of patients who were eligible for inclusion. Nevertheless, it seems clear that extent of primary tumour and serum marker behaviour after orchidectomy are important factors which discriminate between patients with low and high risk of extralymphatic dissemination. In Stage I patients with persistent serum markers there is a high risk of extralymphatic disease, and the treatment of choice is chemotherapy. In patients free of adverse prognostic factors, the relapse rate after lymph-node irradiation is low, and the overall cure rate high if relapses are detected early and treated promptly with chemotherapy (Pechkam et al., 1979 (Pechkam et al., , 1981 . On the other hand, it seems probable that at least 75% of men with Stage I disease and no adverse prognostic factors may be cured by orchidectomy alone. In 1979 radiotherapy was abandoned in this group of patients in favour of a policy of careful follow-up after orchidectomy. To date, of 21 men followed up for at least a year, 4 (19%) have relapsed. All relapses have occurred within 6 months of orchidectomy, and have only been seen in patients with MTU (embryonal carcinoma). All 4 relapsed patients have been successfully treated with chemotherapy for smallvolume disease. The objective of the surveillance study is to define prognostic factors accurately, in order to provide a rational basis for future management. In the retrospective analysis which is described in this report we were unable with confidence to distinguish P2 from P3 tumours, because of limited pathological material. For this reason, unless there is tumour in the proximal spermatic cord, patients are not excluded from the surveillance study. Other potentially important factors, such as lymphatic permeation and vascular invasion within the primary tumour, are being investigated in conjunction with a more detailed study of blood and tissue markers.
